Diagnosis, Targeted therapies: Targeting activators
In this section learn that tyrosine kinases are a family of activator proteins that trigger the cell signaling process leading to cell growth and division.
Targeting activators Tyrosine kinases are a family of activator proteins that trigger the cell signaling process leading to cell growth and division. These kinases are often mutated in cancer. Several anti-cancer drugs have been developed to block specific members of this protein family, including Iressa�„� and Gleevec�„�. Click the forward arrow to find out more about how these drugs work in treating cancer. Charles Sawyer, M.D. is professor of medicine and director of the Prostate Cancer Program Area at U.C.L.A. Johnsson Comprehensive Cancer Center, and an investigator of the Howard Hughes Medical Institute. He works on therapies that target specific mutations in prostate cancer and chronic myeloid leukemia (CML). Here he describes his work developing a targeted therapy for CML patients with resistance to the anti-cancer drug Gleevec. �€œCML stands for chronic myeloid leukemia, which is a blood cancer. It is different from many cancers because it starts very slowly and patients when they're first diagnosed don't have many symptoms. They just have a high white blood cell count that is detected by their physician when they get a routine check up. The incidence of CML is about 5,000 new cases a year in the U.S., another 5,000 in Europe, so, 10,000 patients a year. Patients tend to have CML for five or six years and then, and it's easily controlled with oral chemotherapy drugs until it turns into an aggressive very acute leukemia called blast crisis. And then it becomes a fatal illness. CML is caused by a chromosome translocation known as the Philadelphia chromosome, which occurs in a stem cell in the bone marrow. Presumably a single cell develops that and over a period of years that cell gets a growth advantage and eventually results in a leukemia. The translocation involves two genes. The main gene is a tyrosine kinase called Abl. And the fusion of BCR from one chromosome to Abl on the other creates a kinase that's constantly on. And that enzyme causes this entire disease. We know that by putting this enzyme into a mouse model. You get essential CML in a mouse.�€� �€œSo Gleevec is a pill taken once a day and it is, works remarkably well in all phases of CML. So at the beginning, it was tested in patients with CML who had it for many years and failed standard chemotherapy type treatments. It worked extremely well there, and now is used as front line therapy in essentially all patients with CML. It's taken once a day, there's very little in the way of side effects. Patients live essentially a normal life. If patients are in the later stages' of CML when they start Gleevec, it works quite well, but resistance develops generally after six months to a year. When patients who are newly diagnosed with CML start Gleevec, so far it appears to be working remarkably well for three to four years now of follow-up. That's the longest follow-up we have. But about 15% of patients have developed resistance in that early diagnosis group.�€� �€œThat resistance for the most part is due to the outgrowth of subclones of the CML that have mutations in the Abl kinase domain, right at the places where the Gleevec drug binds. And there are a number of different mutations that have been described and collectively they all share in common the property of interfering with the ability of Gleevec to bind tightly to Abl.�€� �€œThey come about most likely because in the process of growing, the CML clone makes mistakes in DNA replication and generates a diverse repertoire of mutations �€“ most of which are probably irrelevant and just disappear but under the face of selective pressure of a drug, you get outgrowths. They get a growth advantage and they grow up. What's I think is clear is the drug itself is not causing mutations; it's not mutagenic. And when we look using very sensitive tools, it looks like the mutations are already there in most patients and so the die might be cast early on in the disease and it speaks to the need of having perhaps a cocktail of drugs to combat this much like the treatments for HIV virus is based. Well, I can give a number but the natural history of CML is actually a little different now in 2004 than it was four years ago because essentially everyone is now on Gleevec. But if you start on Gleevec in the late stage of the disease, 100% of patients have a resistance within about a year or two. If you start Gleevec at the beginning of the disease, about 15% have resistance within three years. We don't know beyond that what will happen but the curve seems to be continually dropping down gradually but there's no evidence that anyone's been cured with Gleevec and when we use PCR to look for residual CML cells in patients, even those that are doing fantastic, we still see residual cells by PCR. So, most of us believe that there's a reservoir of CML cells left escaping Gleevec, not necessarily expanding but just sitting there. And whether or not that reservoir will be a big problem in another five years of follow-up, we'll just have to see.�€� �€œSo when we had this collection of mutations that were staring at us in the face, we first wanted to understand why did they cause resistance and the reason is they interfere with the ability of the Abl kinase to actually get in the right shape to bind Gleevec. One of the unique properties of Gleevec is that it locks Abl into a certain off configuration, turning the enzyme off.�€� �€œThe kinase has to be pretty flexible to get into that shape. And most of these mutations occur in regions that interfere with this flexibility. So that led to the idea that maybe an inhibitor that would overcome resistance, would in a sense have to be a little sloppier. Maybe not put so many rules on the shape of the Abl kinase.�€� �€œAfter screening through a number of these and talking about this, I was contacted by Bristol-Myers Squibb who had such a compound that was essentially ready for clinical development. It had all the right pharmaceutical properties of a drug rather than just a lab reagent that was tested in mice and so forth and remarkably was effective against all of the Gleevec resistant mutants that we know of, except for one.�€� �€œSo, now patients are on this compound. It's in phase one testing it for patients with CML who have Gleevec resistance in essentially almost all of these patients have these mutations and it looks quite promising in these clinical trials.�€� �€œI think in a more general way, this is a paradigm for how we will do this with the whole range of kinase inhibitors that are not quite as fully developed as the Gleevec story, but are coming along. I think the next example will be lung cancer, for which the EGF receptor happens to be the driver in at least 10% of lung cancer patients in the U.S. due to a mutation that was just recently described. In phase one study. The lung cancer patients in that study, a few of them had some benefit. That led to the decision empirically now to do a large study in lung cancer. And when that was done, about 10 percent of patients had miraculous types of responses. And the in other 90 percent nothing happened so that raises some conundrums for clinical development is obviously you would like to understand what was it about those 10 percent of patients.�€� Iressa targets a tyrosine kinase activator called epidermal growth factor receptor (EGFR). One half of this protein is a receptor on the surface of the cell that binds to signaling molecules. The other half of the protein activates additional proteins inside the cell to trigger cell growth and division. Two things have to happen before EGFR can trigger cell growth and division: a signaling molecule has to bind to the receptor part of EGFR, and a small molecule ATP has to bind to the activator part of EGFR. ATP fuels the reaction. Iressa is a drug that binds to the same part of EGFR as ATP. It prevents ATP from binding, and blocks the growth signal from being sent to the nucleus. Iressa does not work for everyone with lung cancer. In order to understand this, scientists have looked at the sequence of the gene that encodes EGFR in patients that respond to the drug and patients that do not. The patients who respond well to Iressa all have mutations in the ATP-binding region of the EGFR protein. These mutations appear to make the protein bind ATP more tightly, increasing the amount of signal that is passed on to the nucleus. These mutations also appear to make the protein bind Iressa more tightly. It is not yet clear why this makes such a difference in a patient�€™s response to Iressa. It may be that Iressa only affects tumors that are caused by a mutation in EGFR. If so, Iressa would be analogous to Gleevec, a drug that targets the mutant activator protein Bcr-Abl.
chronic myeloid leukemia, cancer drug gleevec, prostate cancer program, hughes medical institute, cml patients, philadelphia chromosome, activator proteins, chemotherapy drugs, blood cell count, acute leukemia, white blood cell, tyrosine kinase, comprehensive cancer center, protein family, charles sawyer, high white blood cell count, blast crisis
- ID: 1012
- Source: DNALC.IC
Professor Charles Sawyer explains that CML stands for chronic myeloid leukemia, which is a blood cancer and it is different from many cancers because it starts very slowly and patients when they're first diagnosed don't have many symptoms.
Conventional cancer drugs are cellular poisons that block replication or some other aspect of cell growth. These drugs affect all cells – healthy or cancerous.
Professor Charles Sawyer explains that Gleevec is a pill taken once a day and works remarkably well in all phases of CML.
Professor Charles Sawyer explains that the CML clone makes mistakes in DNA replication and generates a diverse repertoire of mutations.
Professor Charles Sawyer explains that EGF receptor happens to be the driver in at least 10% of lung cancer patients in the U.S.
15525. How Gleevec works to alleviate symptoms of myeloid leukemia, 3D animation with basic narration
View the animation to find out how the drug Gleevecâ¢ inhibits the molecular cause of chronic myeloid leukemia.
CML causes an increased production of white blood cells. Bud and Yvonne talk about the breakthrough that brought Bud's white blood cell count back to normal.
Brian Druker talks about how the drug he designed targets the molecular cause of CML.
Brian Druker talks about how Gleevec has restored patients' hope for the future.
View the animation to learn about the Philadelphia chromosome, the abnormal chromosome that causes chronic myeloid leukemia.